Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Supernus Pharmaceuticals's average EBITDA Per Share Growth Rate was -110.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -32.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -20.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 5.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Supernus Pharmaceuticals was 97.40% per year. The lowest was -32.80% per year. And the median was -3.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Supernus Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
LTS:0LB2 vs RGC, BCRX, PBH: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -32.80% mean?
Supernus Pharmaceuticals (LTS:0LB2) has a 3-Year EBITDA Growth Rate of -32.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Supernus Pharmaceuticals and its competitors. According to the industry distribution chart, Supernus Pharmaceuticals ranks #762 out of 809 companies in the Drug Manufacturers industry, placing it in the top 94.2%.
Is Supernus Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Supernus Pharmaceuticals' current 3-Year EBITDA Growth Rate is -32.80%. Based on the distribution chart, Supernus Pharmaceuticals ranks #762 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Supernus Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' 3-Year EBITDA Growth Rate compare to RGC and BCRX?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #762 out of 809 companies for 3-Year EBITDA Growth Rate. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current 3-Year EBITDA Growth Rate is -32.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Fairly Valued. The stock's GF Value™ is $44.04, compared to a current price of $46.70 — trading 6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -32.80%. Supernus Pharmaceuticals' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current 3-Year EBITDA Growth Rate is -32.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $46.70 is trading 6% above its estimated GF Value™ of $44.04.
GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0LB2:
3-Year EBITDA Growth Rate: -32.80%
GF Value™: $44.04 vs. price of $46.70 (6% above fair value)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
78GF Score
Get the complete analysis for LTS:0LB2
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
